Several other brokerages have also recently issued reports on CRSP. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. William Blair reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research note on Tuesday, July 30th. BTIG Research lifted their price objective on shares of Crispr Therapeutics from $51.00 to $59.00 and gave the stock a “positive” rating in a research note on Tuesday, July 30th. Chardan Capital set a $72.50 price objective on shares of Crispr Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Jefferies Financial Group started coverage on shares of Crispr Therapeutics in a research note on Thursday, August 1st. They issued a “buy” rating and a $64.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $69.54.
Shares of CRSP stock traded down $0.65 during midday trading on Friday, reaching $68.11. 1,377,268 shares of the company were exchanged, compared to its average volume of 1,496,871. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a market cap of $3.63 billion, a P/E ratio of -19.80 and a beta of 3.15. The company’s 50 day moving average price is $48.67 and its two-hundred day moving average price is $45.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, sell-side analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 over the last ninety days. 21.40% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of CRSP. NEXT Financial Group Inc lifted its stake in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after buying an additional 549 shares during the last quarter. Benjamin Edwards Inc. grew its holdings in shares of Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after purchasing an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth about $26,000. US Bancorp DE grew its holdings in shares of Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares during the last quarter. Finally, BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth about $39,000. Institutional investors and hedge funds own 49.81% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Put Option
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.